EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, VBI Vaccines's enterprise value is $47.14 Mil.
VBI Vaccines's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $8.68 Mil. Therefore, VBI Vaccines's EV-to-Revenue for today is 5.43.
The historical rank and industry rank for VBI Vaccines's EV-to-Revenue or its related term are showing as below:
VBIV'
s EV-to-Revenue Range Over the Past 10 Years
Min: 3.48 Med: 199.02 Max: 945.96
Current: 5.43
During the past 13 years, the highest EV-to-Revenue of VBI Vaccines was 945.96. The lowest was 3.48. And the median was 199.02.
VBIV's EV-to-Revenue is ranked better than 60.54% of 1039
companies
in the Biotechnology industry
Industry Median: 8.37
vs VBIV: 5.43
As of today (2024-05-12), VBI Vaccines's stock price is $0.62.
VBI Vaccines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.49. Therefore, VBI Vaccines's PS Ratio for today is 1.27.
VBI Vaccines EV-to-Revenue Historical Data
The historical data trend for VBI Vaccines's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of VBI Vaccines's EV-to-Revenue
For the Biotechnology subindustry, VBI Vaccines's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VBI Vaccines's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VBI Vaccines's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where VBI Vaccines's EV-to-Revenue falls into.
VBI Vaccines's current Enterprise Value is $47.14 Mil.
VBI Vaccines's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VBI Vaccines's share price for today is $0.62.
VBI Vaccines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.49.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VBI Vaccines EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of VBI Vaccines's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VBIV has been successfully added to your 